

4th World Bronchiectasis & NTM Conference



EMBARC

The European Bronchiectasis Registry

FINAL PROGRAMME

Vers. 1.4 of 18/12/2020

Virtual Edition

16-19 December
2020

Organising Secretariat



Publi Créations

WELCOME

Dear Colleagues and Friends,

It is our great pleasure to welcoming you to the **4th World Bronchiectasis & NTM Conference** virtual edition that will be held from 16 to 19 December 2020.

Page | 2

In a year characterized by the COVID – 19 Pandemic with most of the healthcare resources and energies concentrated in fighting the infection, the World Bronchiectasis Conference remains the place where the latest outcomes on the diagnosis and management of Bronchiectasis are shared and discussed for the benefit and care of chronic and fragile patients.

Furthermore, following the increase of NTM pulmonary and extra – pulmonary morbidity and mortality, it has been decided to fully integrate NTM related topics within the conference programme transforming the WBN – Word Bronchiectasis Conference in WBNC – World Bronchiectasis & NTM Conference.

Considering the complex clinical picture of most of the patients affected by Bronchiectasis and NTM, large space will be given in this edition to **co-morbidities**. A central role would be also dedicated to the latest outcome on **microbiome** in pulmonary diseases as well as in the latest outcomes in **clinical trials**, and new available **diagnostic procedures** and **treatments**. The conference will also be the place to discuss the **International Guidelines on NTM and Bronchiectasis**.

Several lectures would be reserved to **latest and most interesting researches** from all over the World presented directly by participants, while **poster sessions** will help sharing effective clinical practices among attendees.

Joining forces, exchanging clinical experiences, sharing data and instruments, creating a network of active experts in the field are the main goals of the conference.

We look forward to having you all connected,

Yours Sincerely,



Prof. Antoni TORRES



Prof. Francesco BLASI

GENERAL INFORMATION

Live sessions and contents of the

4th World Bronchiectasis & NTM Conference

Page | 3

available on:

www.world-bronchiectasis-conference.org

ORGANISER

SCIENTIFIC & ORGANISING SECRETARIAT



EMBARC

The European Bronchiectasis Registry



Publi Créations

wbc@publiccreations.com

+377 97973555

Organised by



EMBARC

The European Bronchiectasis Registry

Powered by



Publi Créations

CHAIRS

Conference Chair



Professor Antoni Torres (Spain)

Full Professor in Medicine (Pulmonology) at the University of Barcelona and Director of the Respiratory Intensive Care Unit at Hospital Clínic.

Chair of the research group on Applied Research in Respiratory Diseases of the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).

Coordinator of the CIBER group on respiratory diseases (Ciberes), an SGR (Generalitat de Catalonia) group.

Member of EMBARC (The European Bronchiectasis Network) Steering Committee.

Page | 4

Conference Co - Chair



Professor Francesco Blasi (Italy)

Professor of Respiratory Medicine and Head of the Department of Pathophysiology and Transplantation at the University of Milan.

Head Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan.

Member of Board of Directors, Università degli Studi di Milano.

Member of EMBARC (The European Bronchiectasis Network) Steering Committee.

Co-chair of IRIDE, the Italian Registry of adult bronchiectasis.

Co-chair of IRENE the Italian Observatory on Non-Tuberculous Mycobacteria

Former President of ERS – European Respiratory Society.

SCIENTIFIC COMMITTEE

Antoni Torres, Barcelona, Spain

Francesco Blasi, Milan, Italy

Page | 5

Timothy Aksamit, Rochester, USA

Stefano Aliberti, Milan, Italy

James D. Chalmers, Dundee, UK

Wei-Jie Guan, Guangzhou, China

Lucy Morgan, Sydney, Australia

Michal Shteinberg, Haifa, Israel

Montserrat Vendrell, Girona, Spain

Tobias Welte, Hannover, Germany

TOPICS

ABPA - Allergic bronchopulmonary
aspergillosis

Alpha-1 antitrypsin deficiency

Asthma

Biomarkers

Bronchiectasis

Comorbidities

COPD

Cystic Fibrosis

Exacerbations

Genetics

Immunodeficiency

Inhaled Antibiotics

Inhaled Steroids

International Guidelines

Lung Function Testing

Microbiome & Mycobiome

**NTM – Non-Tuberculous
Mycobacteria**

Physiotherapy

PCD - Primary Ciliary Dyskinesia

Registries

Research priorities

RCT – Randomized Clinical Trials

Severity Scores

FACULTY

Tim Aksamit, Rochester, USA
Stefano Aliberti, Milan, Italy
Alan Barker, Portland, USA
Francesco Blasi, Milan, Italy
James D. Chalmers, Dundee, UK
Anne Chang, Brisbane, Australia
Sanjay Chotirmall, Singapore
Tanya Coulter, Belfast, UK
Ernesto Crisafulli, Verona, Italy
Margot de Koning Gans, Christchurch,
New Zealand
David de la Rosa Carrillo, Barcelona, Spain
Antony De Soyza, Newcastle, UK
Raja Dhar, Kolkata, India
Gisli Einarsson, Belfast, United Kingdom
Stuart Elborn, Belfast, UK
Laia Fernandez, Barcelona, Spain
Andreas Floto, Cambridge, UK
Yong-hua Gao, Zhengzhou, China
Timm Greulich, Marburg, Germany
David E. Griffith, Denver, USA
Wei-Jie Guan, Guangzhou, China
Charles Haworth, Cambridge, UK
Adam Hill, Edinburgh, UK
Holly Keir, Dundee - United Kingdom
Michael Loebinger, London, UK
Nicola Lorè, Milan, Italy

Miguel Angel Martinez-Garcia, Valencia,
Spain
Aurora Massaguer, Girona, Spain
Jennifer Meerburg, Rotterdam,
The Netherlands
Rosario Menendez, Valencia, Spain
Mark Metersky, Farmington, USA
Anne O'Donnell, Washington DC, USA
Lucy Morgan, Sydney, Australia
Kenneth Olivier, Bethesda, USA
Constança Pascual, Girona, Spain
Eva Polverino, Barcelona, Spain
Felix Ringshausen, Hannover, Germany
Jodie Schildkraut, Nijmegen,
The Netherlands
Leopoldo Segal, New York, USA
Michal Shteinberg, Haifa, Israel
Oriol Sibila, Barcelona, Spain
Gregory Tino, Philadelphia, USA
Antoni Torres, Barcelona, Spain
Jakko van Ingen, Nijmegen,
The Netherlands
Montserrat Vendrell, Girona, Spain
Nicola Veziris, Paris, France
Alexandru D. Vlagea, Barcelona, Spain
Tobias Welte, Hannover, Germany
Kevin Winthrop, Portland, USA

POSTER PRESENTERS

Presenters	Poster N.	See Page
Abo-Leyah Hani	19.b.1	16
Alcaraz Victoria	19.b.9	16
Alfahl Zina	19.a.1	15
Alhamed Alduihi Fatima	19.a.2	15
Alkarni Meyad	18.c.1	14
Athanazio Rodrigo Abensur	18.a.1	12
Athanazio Rodrigo Abensur	18.a.2	12
Bhatnagar Malvika	19.a.3	15
Blamires Julie	19.a.4	15
Bradley Judy M.	19.a.5	15
Bradley Judy M.	19.a.6	15
Bueno Freire Leticia	19.a.7	15
Cabrera Roberto	18.a.3	12
Crichton Megan L.	18.a.4	12
De Vuono Maria Carmela	18.a.5	12
Dente Federico Lorenzo	19.c.1	17
Di Michiel James	19.c.5	17
Durand Patricia	19.b.5	16
Gao Yong-hua	19.a.8	15
Giam Yan Hui	18.a.6	12
Glodić Goran	18.a.7	12
Jakharia Kunal	18.c.9	14
Karamooz Elham	18.a.8	12
Keir Holly	19.c.3	17
Kim Soo Han	19.a.9	15
Laorden Daniel	19.b.6	16
Latisenko Rudolfs	19.b.2	16
LeClerc Isabelle	18.a.9	12
Lee Annemarie	19.c.8	17
Lotte Terpstra	18.a.10	12

Presenters	Poster N.	See Page
Lv Qianting	19.b.7	16
Mäntylä Jarkko	18.a.11	12
Mariscal Aguilar Pablo	18.c.2	14
Maselli Diego	18.b.10	13
McLeese Rebecca H.	18.b.1	13
Méndez Raúl	19.b.10	16
Mingora Christina	18.c.3	14
Morin Laurent	19.c.7	17
Nguyen Tu Quan	19.c.10	17
O' Donoghue Aisling	19.c.9	17
Obradovic Marko	18.c.4	14
Obradovic Marko	18.c.5	14
Obradovic Marko	18.c.6	14
O'Neill Katherine	18.b.2	13
O'Neill Katherine	18.b.3	13
Oriano Martina	18.b.4	13
Panciu Traian Constantin	18.b.9	13
Perea Lidia	19.b.3	16
Ray Animesh	19.a.10	15
Richardson Hollian	19.c.4	17
Sadigov Alizaman	19.c.2	17
Saliu Fabio	19.b.8	16
Shteinberg Michal	18.b.5	13
Smalley Katelyn	18.b.6	13
Spinou Arietta	18.b.7	13
Suska Kseniia	19.b.4	16
Taylor Steven	19.c.6	17
Torrente Anna	18.b.8	13
Wang Ping	18.c.8	14

SCIENTIFIC PROGRAMME

reported times are CET (Central Europe Time)

Page | 8

16TH DECEMBER from 13.00 to 15.00 (CET)

LIVE SESSION DAY 1

Following participants' request the "Meet the Professors" sessions will be only the following two

Registrations for the below Courses will be open up to December 8th.

PRE – REGISTRATION COMPULSORY

Only 30 places available per course, confirmed on a first come first served basis

13.00 – 14.00

MEET THE PROFESSORS – ROUND 1

Meet the Professors D

Immunodeficiency: from diagnosis to management

Tanya Coulter, Belfast, UK - Alexandru Daniel Vlaga, Barcelona, Spain

14.00 – 15.00

MEET THE PROFESSORS – ROUND 2

Meet the Professors A

NTM – PD: the challenging diagnostic path

David E. Griffith, Denver, USA - Michael Loebinger, London, UK

17TH DECEMBER from 12.30 to 16.00 (CET)

LIVE SESSION DAY 2

12.30 – 12.40

OPENING ADDRESS

Antoni Torres, Barcelona (Spain)
Francesco Blasi, Milan (Italy)
James D. Chalmers, Dundee (UK)

Page | 9

12.40 – 13.25

RISING STARS SESSION

Chairs: Antoni Torres, Barcelona (Spain), Francesco Blasi, Milan (Italy)

12.40 - 12.55

Rising Star Oral presentation (Bronchiectasis)

Sputum proteomics identifies mechanisms of disease severity and treatment response in bronchiectasis

Holly Keir, Dundee, UK

5' questions time

13.00 - 13.15

Rising Star Oral presentation (NTM – PD)

Dual RNA-Seq of *M. avium* identifies characteristic host-pathogen interactions

Jodie Schildkraut, Nijmegen, The Netherlands

5' questions time

13.20 - 13.25

Advice from Chairs to Rising Stars

13.25 – 13.55

KEYNOTE LECTURE

Chair: Oriol Sibila, Barcelona (Spain)

New bronchiectasis management in the COVID19 era

Tobias Welte, Hannover, Germany

13.55 – 15.30

**SESSION I: NOVEL DIAGNOSTICS AND ASSESSMENT
METHODS**

Chairs: Felix Ringshausen, Hannover (Germany),
Michael Loebinger, London (UK)

Page | 10

13.55 – 14.15

Lung Function Testing Findings

Wei-Jie Guan, Guangzhou, China

14.15 – 14.35

Biomarkers to assess severity & prognosis

Stefano Aliberti, Milan, Italy

14.35 – 14.55

**Quantitative chest computed tomography scoring technique for
bronchiectasis (BEST-CT)**

Jennifer Meerburg, Rotterdam, The Netherlands

14.55 – 15.15

Genetics and Bronchiectasis

Kenneth Olivier, Bethesda, USA

15.15 – 15.30

Discussion

15.30 -16.00

VIRTUAL COCKTAIL

18TH DECEMBER from 12.30 to 17.00 (CET)

LIVE SESSION DAY 3

12.30 – 13.30

SESSION II: INHALED TREATMENTS

Page | 11

Chairs: James D. Chalmers, Dundee (UK),
David de la Rosa Carrillo, Barcelona (Spain)

12.30 – 12.50

Should we need Inhaled Steroids?

Margot de Koning Gans, Christchurch, New Zealand

12.50 – 13.10

Inhaled antibiotics: the iBest Example

Charles Haworth, Cambridge, United Kingdom

13.10 – 13.20

Effect of treatment with the TOBI Podhaler® on the airway microbiota in
Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study

Gisli Einarsson, Belfast, United Kingdom

13.20 – 13.30

Discussion

13.30 – 14.30

SESSION III: FOCUS ON NON-TUBERCULOUS MYCOBACTERIA

Chair: Miguel Angel Martinez-Garcia, Valencia (Spain),
Kevin Winthrop, Portland (USA)

13.30 – 13.50

NTM transmission: state of the art

Andreas Floto, Cambridge, UK

13.50 – 14.10

International guidelines on NTM

Jakko van Ingen, Nijmegen, The Netherlands

14.10 – 14.20

Unravelling the role of type 1 interferons in lung chronic infections by M.
Abscessus

Nicola Lorè, Milan, Italy

14.20 – 14.30

Discussion

14.30 – 15.30

LIVE SPONSORED SYMPOSIUM *Please refer to page 21 for details*

18TH DECEMBER

POSTER SESSIONS

December 18th, 15.45 – 17.00 (CET)

Poster Session 18.a, 15.45 – 17.00 (CET)

Page | 12

Topics: Bronchiectasis, Lung Function Testing

Chairs: Michal Shteinberg (Israel)
Antoni Torres (Spain)
Tobias Welte, Hannover (Germany)

	Presenter	Nationality	Abstract Title
18.a.1	Athanazio Rodrigo Abensur	Brazil	Automated computed tomography lung densitometry in bronchiectasis patients
18.a.2	Athanazio Rodrigo Abensur	Brazil	Dynamic Hyperinflation and Exercise Intolerance in Bronchiectasis: Clinical, Radiological and Functional Correlation
18.a.3	Cabrera Roberto	Spain	High levels of resistance to recommended antimicrobial agents in Pseudomonas aeruginosa from patients with bronchiectasis
18.a.4	Crichton Megan L.	United Kingdom	Validation of the Bronchiectasis Impact Measure (BIM) – a novel patient reported outcome measure
18.a.5	De Vuono Maria Carmela	Italy	Voice of Patients in Bronchiectasis - a social media analysis
18.a.6	Giam Yan Hui	United Kingdom	Validation of AMP-activated protein kinase as a therapeutic target in bronchiectasis
18.a.7	Glodić Goran	Croatia	First Description of Bronchiectasis characteristics in Croatian patients – Data from the European Multicenter Bronchiectasis Audit and Research Collaboration
18.a.8	Karamooz Elham	United States of America	Pulmonary hypertension in bronchiectasis: A CT analysis from a cohort of the US Bronchiectasis and NTM Research Registry
18.a.9	LeClerc Isabelle	Canada	Innovative! Bronchiectasis! Education! Primary Care!
18.a.10	Lotte Terpstra	The Netherlands	Effects of long-term Tobramycin Inhalation Solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis The BATTLE Randomized Controlled Trial
18.a.11	Mäntylä Jarkko	Finland	Poor Physical Capacity in Bronchiectasis Patients Is Correlated with Poor Quality of Life

Poster Session 18.b, 15.45 – 17.00 (CET)

Topic: **Bronchiectasis**

Chairs: Timothy Aksamit, Rochester (USA)
James D. Chalmers (UK)

Page | 13

	Presenter	Nationality	Abstract Title
18.b.5	Shteinberg Michal	Israel	Exploring factors associated with acquisition and chronicity of infection in bronchiectasis: a population based study
18.b.1	McLeese Rebecca H.	United Kingdom	Psychometric properties of health-related quality of life questionnaires for use in bronchiectasis clinical trials: A systematic review and meta-analysis
18.b.2	O'Neill Katherine	United Kingdom	Follow-up respiratory physiotherapy in bronchiectasis: A Northern Ireland survey
18.b.3	O'Neill Katherine	United Kingdom	Changes in Lung Clearance Index in the iBEST-1 study
18.b.4	Oriano Martina	Italy	Clinical characteristics associated with low sputum microbiome diversity in bronchiectasis
18.b.6	Smalley Katelyn	United Kingdom	Co-designing a digital self-management plan for bronchiectasis
18.b.7	Spinou Arietta	United Kingdom	Use of nebulized medications in people with bronchiectasis: a questionnaire for respiratory specialists
18.b.8	Torrente Anna	Spain	Screening non-tuberculous mycobacteria in patients with non-cystic fibrosis bronchiectasis
18.b.9	Panciu Traian Constantin	Romania	Insight into a Romanian group of bronchiectasis patients
18.b.10	Maselli Diego	United States of America	Small Airway Disease and Emphysema are Associated With Future Exacerbations in Smokers With Bronchiectasis

Poster Session 18.c, 15.45 – 17.00 (CET)

**Topics: NTM – Non-Tuberculous Mycobacteria,
PCD – Primary Ciliary Dyskinesia**

Chairs: Stefano Aliberti (Italy)
Francesco Blasi (Italy)
Montserrat Vendrell (Spain)

Page | 14

	Presenter	Nationality	Abstract Title
18.c.1	Alkarni Meyad	United Kingdom	Neutrophil mediated control of Non Tuberculous Mycobacteria in patients with primary hypogammaglobulinaemia
18.c.2	Mariscal Aguilar Pablo	Spain	Comparison of spirometric changes in two different groups of patients with microbiological culture of Mycobacterium Abscessus.
18.c.3	Mingora Christina	United States of America	Time-to-detection as a pre-treatment predictor for culture conversion in patients with Non Tuberculous Mycobacteria Pulmonary Disease.
18.c.4	Obradovic Marko	Germany	Baseline characteristics and real-world treatment patterns of non-tuberculous mycobacterial lung disease (NTMLD) patients in community care setting in Germany
18.c.5	Obradovic Marko	Germany	Burden of non-tuberculous mycobacterial lung disease (NTMLD) in France: a claim database analysis
18.c.6	Obradovic Marko	Germany	Patient reported burden of Nontuberculous Mycobacterial Lung Disease (NTM-LD) – a patient survey in Germany
18.c.8	Wang Ping	United States of America	The Incremental Burden of Nontuberculous Mycobacterial Lung Disease (NTMLD) Among Patients with Bronchiectasis (BE): Hospitalizations and ER Visits Among US Medicare Beneficiaries
18.c.9	Jakharia Kunal	United States of America	Diagnostic Challenges in PCD: Need for Multiple Approaches

LIVE SESSIONS DAY 4

POSTER SESSIONS

December 19th, 11.00 – 12.30 (CET)

Page | 15

Poster Session 19.a, 11.00 – 12.30 (CET)

Topic: Bronchiectasis

Chairs: Stefano Aliberti (Italy)
Wei-Jie Guan (China)
Antoni Torres (Spain)

	Presenter	Nationality	Abstract Title
19.a.1	Alfahl Zina	United Kingdom	Longitudinal assessment of sputum total bacterial, Pseudomonas aeruginosa and Haemophilus influenzae load in people with bronchiectasis when clinically stable and at the start and end of treatment of an exacerbation: Data from the BRONCH UK Study
19.a.2	Alhamed Alduihi Fatima	Syrian Arab Republic	CT findings in patients with Bronchiectasis
19.a.3	Bhatnagar Malvika	United Kingdom	Redesigning Bronchiectasis outpatient services post COVID-19 using patient satisfaction and preference data
19.a.4	Blamires Julie	New Zealand	Sore and Tired. The symptom experience of young people with bronchiectasis.
19.a.5	Bradley Judy M.	United Kingdom	Clinimetrics properties of objective outcome measures in the BronchUK study
19.a.6	Bradley Judy M.	United Kingdom	Clinimetrics properties of patient reported outcome measures to measure health-related quality of life in the BronchUK study
19.a.7	Bueno Freire Leticia	Spain	Longitudinal assessment of health-related quality of life in patients with bronchiectasis colonized by Pseudomonas aeruginosa
19.a.8	Gao Yong-hua	China	Detection and Quantification of microbiologic profiles of sputum at exacerbation in patients with bronchiectasis by using BioFire FilmArray Pneumonia Panel
19.a.9	Kim Soo Han	Korea (Republic of)	The characteristics and risk factors of bronchiectasis based on respiratory symptoms among the subjects who performed a medical check-up in a health-screening center
19.a.10	Ray Animesh	India	A study on the diagnostic accuracy of CT parameters for identification of recurrence of tuberculosis in post-tubercular bronchiectasis patients: Data from follow-up of 223 patients over 5 years

Organised by



EMBARC

The European Bronchiectasis Registry

Powered by



Publi Créations

Poster Session 19.b, 11.00 – 12.30 (CET)

Topics: Biomarkers, Cystic Fibrosis, Exacerbations

Chairs: Francesco Blasi (Italy)
Montserrat Vendrell (Spain)
Tobias Welte (Germany)

Page | 16

	Presenter	Nationality	Abstract Title
19.b.1	Abo-Leyah Hani	United Kingdom	Proteinase-3 as a biomarker of exacerbation in bronchiectasis
19.b.2	Latisenko Rudolfs	The Netherlands	Airway Path Tapering and Total Airway Count quantified on CT for Assessment of Bronchiectasis
19.b.3	Perea Lidia	Spain	Salivary SLPI and disease severity in Bronchiectasis
19.b.4	Suska Kseniia	Ukraine	Visceral fat as a predictor of the development of the T-helpers Type 2 airways inflammation in Bronchiectasis.
19.b.5	Durand Patricia	Romania	Imaging features encountered in children with cystic fibrosis
19.b.6	Laorden Daniel	Spain	Comparative study of Mycobacterium abscessus infection between cystic fibrosis patients and non cystic fibrosis patients
19.b.7	Lv Qianting	The Netherlands	Computer aided diagnosis (CAD) for monitoring CF airway disease (CAD), the CAD-CAD method
19.b.8	Saliu Fabio	Italy	Nontypeable Haemophilus influenzae drives airway inflammation upon chronic infection
19.b.9	Alcaraz Victoria	Spain	Association between physical activity and risk of hospitalisation in bronchiectasis
19.b.10	Méndez Raúl	Spain	Acute and sustained IL-17a response in bronchiectasis exacerbations

Poster Session 19.c, 11.00 – 12.30 (CET)

Topics: Asthma, Comorbidities, Microbiome & Mycobiome, PCD - Primary Ciliary Dyskinesia, Physiotherapy, Registries

Chairs: James D. Chalmers (UK)
Lucy Morgan (Australia)
Michal Shteinberg (Israel)

Page | 17

	Presenter	Nationality	Abstract Title
19.c.1	Dente Federico Lorenzo	Italy	Asthmatic traits in a group of patients with non cystic fibrosis Bronchiectasis
19.c.2	Sadigov Alizaman	Azerbaijan	Risk Factors for All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease: a 10-year follow-up study
19.c.3	Keir Holly	United Kingdom	Elevated sputum neutrophil elastase is predictive of microbiome dysbiosis and disease severity in bronchiectasis
19.c.4	Richardson Hollian	United Kingdom	Short-term stability of the lung microbiome in bronchiectasis and cystic fibrosis
19.c.5	Di Michiel James	Australia	Mucociliary clearance in the healthy trachea occurs in spirals and is impaired in COPD, and absent in primary ciliary dyskinesia and acute viral infection
19.c.6	Taylor Steven	Australia	Exploring the relationship between Pseudomonas aeruginosa, inflammation and bronchiectasis in a lung explant from a patient with primary ciliary dyskinesia
19.c.7	Morin Laurent	France	Feasibility and benefits of an innovative airway clearance device in COPD patients hospitalized for acute exacerbation
19.c.8	Lee Annemarie	Australia	"Teach me how to look after myself" - what people with bronchiectasis want from education in a pulmonary rehabilitation setting
19.c.9	O' Donoghue Aisling	United Kingdom	The design and implementation of a Bronchiectasis Discharge Care Bundle
19.c.10	Nguyen Tu Quan	Australia	The Australian Bronchiectasis Registry: revision and improvement of a critical data collection platform to inform clinical care of bronchiectasis in Australia

19TH DECEMBER

LIVE SESSION DAY 4

12.30 – 13.20

SESSION IV: MICROBIOME NEW FRONTIERS

Page | 18

Chairs: Michal Shteinberg, Haifa, Israel
Stefano Aliberti, Milan, Italy

12.30 – 12.45

Eradication in the era of microbiome

James D. Chalmers, Dundee, UK

12.45 – 13.00

Functional effects of the microbiome / mycobiome

Sanjay Chotirmall, Singapore, Singapore

13.00 – 13.15

Pseudomonas aeruginosa leading pathogen in the bronchiectasis microbiota?

Antoni Torres, Barcelona, Spain

13.15 – 13.20

Discussion

13.20 – 13.50

SPONSORED CASE HISTORIES DISCUSSION

Please refer to page 21 for details

13.50 – 15.15

SESSION V: BRONCHIECTASIS ASSOCIATED DISEASES

Chairs: Gregory Tino, Philadelphia, USA
Anne O'Donnell, Washington DC, USA

13.50 - 14.05

Bronchiectasis & NTM

Felix Ringshausen, Hannover, Germany

14.05 - 14.20

Bronchiectasis in Severe Asthma: combined treatment options

Francesco Blasi, Milan, Italy

14.20 - 14.35

Management of COPD and Bronchiectasis

Ernesto Crisafulli, Verona, Italy

14.35 - 14.50

Alpha-1 antitrypsin deficiency

Timm Greulich, Marburg, Germany

14.50 - 15.05

Aspergillus in Bronchiectasis

Antony De Soyza, Newcastle, UK

15.05 – 15.20

Discussion

15.20-15.30

CLOSING ADDRESS & BEST POSTER AWARDS

Chairs: Antoni Torres, Barcelona (Spain), Francesco Blasi, Milan (Italy),
James D. Chalmers, Dundee (UK)

SESSIONS AVAILABLE ON DEMAND ONLY (pre-recorded)

SESSION A: CLINICAL TRIALS

Chair: Alan Barker, Portland (USA)

Page | 19

- | | |
|------------|---|
| 20 MINUTES | Brensocatib in Bronchiectasis – WILLOW Study
<i>James D. Chalmers, Dundee, UK</i> |
| 20 MINUTES | Placebo effects in bronchiectasis
<i>Yong-hua Gao, Zhengzhou, China</i> |
| 15 MINUTES | Discussion |

SESSION B: FOCUS on Bronchiectasis

Chair: Michael Loebinger, London (UK)

- | | |
|------------|---|
| 20 MINUTES | Bronchiectasis insanity
<i>Mark Metersky, Farmington, USA</i> |
| 20 MINUTES | Implications of Pseudomonas aeruginosa biofilms in diagnosis, respiratory dysbiosis and exacerbations in non-Cystic Fibrosis Bronchiectasis
<i>Laia Fernandez-Barat, Barcelona, Spain</i> |
| 10 MINUTES | Discussion |

SESSION C: THE PATIENTS' POINT OF VIEW

Chair: Montserrat Vendrell, Girona (Spain)

- | | |
|------------|---|
| 15 MINUTES | My experience with Bronchiectasis
<i>Constança Pascual, Girona, Spain</i> |
| 15 MINUTES | My experience with NTM
<i>Aurora Massaguer, Girona, Spain</i> |
| 10 MINUTES | Discussion |

LECTURES AVAILABLE ON DEMAND ONLY (pre-recorded)

30 MINUTES

Keynote lecture 1

Bronchiectasis: need for better definitions

Rosario Menendez, Valencia, Spain

Page | 20

30 MINUTES

Keynote lecture 2

Research priorities in pulmonary NTM

Timothy Aksamit, Rochester, USA

30 MINUTES

Keynote lecture 3

Microbiome in Bronchiectasis and in NTM infections

Leopoldo Segal, New York, USA

30 MINUTES

KEYNOTE lecture 4

Lessons learnt from CF: implications for bronchiectasis

Stuart Elborn, Belfast, UK

20 MINUTES

LECTURE 1

Adultologists meet paediatricians: what are we supposed to know from our patient's childhood that has an impact on the adulthood management

Adam Hill, Edinburgh, UK

20 MINUTES

LECTURE 2

Bronchiectasis exacerbation management

Anne Chang, Brisbane, Australia

20 MINUTES

LECTURE 3

Bronchiectasis: Dirty Little Secrets

Lucy Morgan, Sydney, Australia

20 MINUTES

LECTURE 4

Role of Registries: the Indian Example

Raja Dhar, Kolkata, India

SPONSORED SESSIONS

The following sessions are not part of the CME programme, both for UEMS/EAACME and EBAP procedures. Participants cannot claim credits for attending the following sessions

Page | 21

LIVE SESSION DAY 3

18TH DECEMBER from 14.30 to 15.30 (CET)

LIVE SPONSORED SYMPOSIUM

Looking ahead - the changing landscape of MAC lung infection

Co-chairs Professor **Stefano Aliberti** and Professor **Eva Polverino** are joined in this roundtable session by an expert panel of Professor **Michael Loebinger** and Professor **Nicolas Veziris** to discuss their personal insights into the management of NTM.

Topics for discussion include:

- *Advances and challenges in NTM management in 2020*
- *Impact of the 2020 NTM guidelines on clinical practice*
- *Role for new treatment options in MAC pulmonary disease*

Supported by Insméd

LIVE SESSION DAY 4

19TH DECEMBER from 13.20 to 13.50 (CET)

LIVE CASE HISTORIES DISCUSSION

The bronchiectasis diagnostic conundrum: Results and implications from the pre-congress survey

Chair: Antoni Torres, Barcelona (Spain)

Speaker: Montserrat Vendrell, Barcelona (Spain)

Supported by Grifols

GENERAL INFORMATION

VIRTUAL EDITION

The 4th World Bronchiectasis & NTM Workshop is realised in virtual format.

The virtual platform IS accessible only for registered participants from December 9th, 2020 to June 30th, 2021.

As per December 9th, 2020 registered participants may access the:

- Pre-recorded sessions
- Pre-recorded lectures and keynote lectures
- Published Poster Presentations in the Poster Lounge Area

Live sessions as per scientific programme will take place on December 16th – 19th. Check the programme for timing.

The live sessions are recorded and made available to all registered participants from December 23rd, 2020 to June 30th, 2021.

Page | 22

PERSONAL CREDENTIALS

To access the 4th WBNC Virtual Platform use the credential you received when registering and reconfirmed with the confirmation letter received at beginning of December.

Credentials are strictly personal and you should not share them with colleagues.

Free name changes are always possible, please write to wbc@publiccreations.com. Name changes are guaranteed before December 15th and could not be so immediate during the dates of the live.

Please note that each set of credential provides ONLY ONE ACCESS to the platform.

PERSONAL DATA

If you have accepted to be listed in the Participants List the following data will be visible to other participants.

- Picture (if provided)
- Surname / Name
- Role
- Department
- Institution / Company and address
- Telephone
- Email
- Website

NB: The mobile phone is used only by the secretariat and will not be published.

At any moment you can access from the platform the page "My Profile" and change the authorisation status.

Please note that if you do not provide authorisation to share your data with the other registered participants you cannot access the data of other participants.

DIFFERENTIATED ACCESSES

Some contents are dedicated to Healthcare Professionals and cannot be accessed by other professionals.

Healthcare Professionals and **Pharma Company staff members** may access all the content of the platform with the exception of the Press Room.

Patient Associations Representatives may access all the content of the platform with the exception of promotional contents by Pharma Companies and Press Room.

Only **Speakers** can access the "Speakers Ready Room".

Only **Poster Presenters** and **Speakers** can access the "Poster Presenters Ready Room"

Page | 23

SPEAKERS READY ROOM

Only Speakers can access the Speakers Ready Room.

The speakers ready room is accessible every day from half an hour before the beginning to the end of the live programme. More precisely the Speakers ready room will be available in the following periods:

December 16th – From 12:30 to 15:00 (CET Time)

December 17th – From : 12:00 to 16:00 (CET Time)

December 18th – From 12:00 to 17:00 (CET Time)

December 19th – From 10:30 to 15:30 (CET Time)

POSTER PRESENTERS READY ROOM & POSTERS SESSIONS

Poster Presenters and Speakers can access the Poster Presenter Ready Room starting from 30 minutes before each poster session. The Direction will split the poster presenters in the different poster sessions held in parallel.

Refer to the Scientific Programme to check which is the poster session your poster presentation is discussed in

Each poster presentation should not exceed 5 minutes.

The best posters will receive the 4th **WBNC Poster Award**. Winners are disclosed in the Closing Address on December 19th at 15:20 (CET)

Poster Awards winners will benefit of recognition on the congress website and Abstracts Book and benefit of a free registration for the 2nd European NTM & Bronchiectasis Conference planned in Milan on July, 1st – 3rd, 2021.

LIVE QUESTION CHATS AND LIVE POLL

The participation to live question chats and live polls during the live sessions is facultative.

NETWORKING OPPORTUNITIES

In the **Networking Lounge** you can see who is connected in each moment, chat with the other participants (general chat of the congress).

Furthermore, accessing the **participants list** you may download the virtual "**Business Card**" of other registered participants who have authorised, as yourself, to share their data. The Business Card includes e-mail and phone number to start, eventually, a personal conversation.

Also the side bar offers you the possibility to see who is on line in each moment. Please note that the person you call can refuse the call.

Page | 24

PRESENCE CONTROL

The virtual platform allows the Congress Secretariat to follow the path done by each participants within the platform.

These data are strictly confidential and are used only for:

- Issue a Certificate of Attendance only to attendees effectively present during the days of the live congress
- Issue CME Credits Certificate to attendees who have effectively followed the sessions.

The attendees who have authorised the publication of their data may share them with the relevant sponsor while entering their specific Partner Corporate Page

CERTIFICATE OF ATTENDANCE

The certificate of attendance is downloadable from the website at www.world-bronchiectasis-conference.org using the personal log-in credentials sent by e-mail, starting from December 22nd 2020.

For Sponsored Groups: Please note that in order to provide the certificate of attendance to each participant, we need the personal e-mail address.

The Certificate of attendance will only be delivered to those having attended the Conference.

CME ACCREDITATION

4th World Bronchiectasis & NTM Conference, 16/12/2020-19/12/2020 has been granted 16 European CME credits by the European Board for Accreditation in Pneumology (EBAP) and **8 CME credits (ECMEC®s)** by the European Accreditation Council for Continuing Medical Education (EACCME®)

The Credits Certificate is only be delivered to those having attended the Conference.

To download your certificate please log in the website www.world-bronchiectasis-conference.org using the personal log-in credentials sent by e-mail, starting from December 22nd, 2020. CME Credits certificates are downloadable up to January 11th. After this date, in order to comply with the reporting deadline of UEMS, the CME Credits are no longer downloadable.

For Sponsored Groups: Please note that in order to provide the CME certificate to each participant, we will need their personal e-mail address.

LANGUAGE

The official language of the Conference is English. No simultaneous translation will be provided.



2nd European NTM & Bronchiectasis Workshop

Milan, Università Statale
01 - 03 July 2021



■ ORGANISING COMMITTEE

STEFANO ALIBERTI (*Italy*)
FRANCESCO BLASI (*Italy*)
JAMES D. CHALMERS (*UK*)

► SCIENTIFIC COMMITTEE

STUART ELBORN (*UK*)
PIETER C. GOEMINNE (*Belgium*)
CHARLES S. HAWORTH (*UK*)
MICHAEL LOEBINGER (*UK*)
ANTONI TORRES (*Spain*)
TOBIAS WELTE (*Germany*)

TOPICS

- ◆ *Bronchiectasis*
- ◆ *Cystic Fibrosis*
- ◆ *Epidemiology*
- ◆ *Etiology*
- ◆ *Exacerbations*
- ◆ *Imaging*
- ◆ *Immunology*

- ◆ *International Guidelines*
- ◆ *Modifiable risk factor*
- ◆ *NTM*
- ◆ *Paediatrics*
- ◆ *Treatments*
- ◆ *Surgery*

Powered by



Publi Créations



CALL FOR ABSTRACT
March 29th, 2021

www.ntmbronchiectasis.org
mail: ntmbronchiectasis@publiccreations.com

The Committee is grateful to

Platinum Sponsor



Gold Sponsors



GRIFOLS

Supporter



Media Partner





4th World Bronchiectasis & NTM Conference



EMBARC
The European Bronchiectasis Registry

Virtual Edition

16-19 December 2020

www.world-bronchiectasis-conference.org

Organising Secretariat



Publi Créations

Page | 28



Organised by
EMBARC

The European Bronchiectasis Registry

Powered by



Publi Créations